Vir Biotech Smashes Q4 Expectations + Lands $1.7B Prostate Cancer Deal!

Vir Biotech beats Q4 estimates by a mile, announces $335M+ partnership with Astellas, and shares promising new data for its prostate cancer drug. Strong cash position funds operations into 2028.